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Background: Drug-resistant TB has emerged as a major challenge facing TB prevention and control efforts. In
Ethiopia, the extent/trend of drug resistance TB is not well known. The aim of this study was to determine the
pattern and trend of resistance to first line anti-TB drugs among culture positive retreatment cases at St.Peter’s TB
Specialized Hospital.
Findings: A hospital based retrospective study was used to assess the pattern of anti-TB drug resistance among
previously treated TB patients referred to St.Peter’s TB Specialized Hospital from January 2004-December 2008
Gregorian calendar(GC) for better diagnosis and treatment.
Among 376 culture positive for M. tuberculosis one hundred and two (27.1%) were susceptible to all of the four first
line anti-TB drugs -Isoniazid (INH), Rifampicin (RIF), Ethambutol (ETB) & Streptomycin (STM). While 274 (72.9%) were
resistant to at least one drug. Any resistance to STM (67.3%) was found to be the most common and the
prevalence of MDR-TB was 174 (46.3%). Trend in resistance rate among re-treatment cases from 2004 to 2008
showed a significant increase for any drug as well as for INH, RIF, and MDR resistance (P <0.05 for trend).
Conclusions: There has been an increasing trend in drug resistance in recent years, particularly in retreatment
cases. Therefore, establishing advanced diagnostic facilities for early detection of MDR-TB and expanding second
line treatment center to treat MDR-TB patients and to prevent its transmission is recommended.
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Tuberculosis (TB) is a disease impacting public health
problem worldwide that disproportionately affects peo-
ples in resource-poor settings, particularly those in Asia
and Africa. More than 90% of new TB cases and deaths
occur in developing countries [1,2].
According to the 2011 WHO global TB report, Ethi-
opia ranks 7th in the list of the world’s 22 high burden
countries for TB with estimated incidence rate to be
261/100,000, mortality rate 35/100,000 and the preva-
lence of all forms TB is estimated to be 394/100,000 [2].
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reproduction in any medium, provided the orinfected with TB [3]. Recently the country has massively
engaged in early case detection, provision of adequate
chemotherapy and prevention of transmission to new
cases [4]. Despite such efforts, the emergence of drug re-
sistant tuberculosis strains that cannot be cured by
standard anti-tuberculosis drug regimens considered as
devastating threat to TB control program [5]. Drug re-
sistant tuberculosis commonly arises through the selec-
tion of mutated strains by inadequate chemotherapy.
Resistance to at least the two major anti-tuberculosis
drugs, isoniazid and rifampicin has been termed as
multidrug-resistant tuberculosis (MDR-TB). Treatment
of MDR-TB requires prolonged and expensive chemo-
therapy using second line drugs of heightened toxicity
and less effective [6,7].
According to WHO Global TB report, Ethiopia is
ranked as 15th among 27 high burden M(X) DR-TB
countries. The estimated MDR rate was (0.9%–2.8%) fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Despite the availability of a national estimate, it has been
noted that continues evaluation of ongoing treatment
program is one of the important aspects in the assess-
ment of TB epidemiology [8,9]. Therefore, the present
study was to determine the pattern and trend of resist-
ance to first line anti-TB drugs among culture positive
retreatment cases at St. Peter’s TB Specialized Hospital
in Addis Ababa, Ethiopia.
Methods
Research setting and context
St. Peter’s TB specialized hospital was established in
June, 1961 Gregorian Calendar (GC). It is a governmen-
tal hospital under Federal Democratic Republic of
Ethiopia- Ministry of Health (FMOH). The hospital pro-
vides various services especially in tuberculosis diagnosis
and treatment. It serves as a referral TB hospital in
Addis Ababa, Ethiopia and has a vision to become Cen-
ter of Excellence for diagnosis and treatment of TB in
East Africa.
Study design and participants
A Hospital based retrospective study was conducted in
Addis Ababa from February 2010 to March 2010 GC to as-
sess the patterns of resistance to anti-TB drugs among pre-
viously treated TB patients referred to St. Peter’s TB
Specialized Hospital. Participants for this study were all
previously treated TB cases from January 2004 – December
2008 GC. The study subjects already received the standard
first line anti-TB treatment for more than one month but
still had positive smears and had to be started on a retreat-
ment regimen (2 S (ERHZ)/1(ERHZ)/5 E3 (RH)3. The hos-
pital provides for those patients refereed to the hospital
across the country as the hospital serve as a referral point
for tuberculosis management for the country.
Drug susceptibility test
The drug susceptibility tests were done at Ethiopian
Health and Nutrition Research Institute (EHNRI) TB La-
boratory. The laboratory used Löwenstein-Jensen (L-J)
culture medium on which the specimen was inoculated
after decontamination with sodium hydroxide (4%).
Identification of isolates was based on the niacin produc-
tion test, the nitrate reduction test the para-nitrobenzoic
(PNB) acid (500 mg/l) test, and the thiophene-2-
carboxylic acid hydrazide (TCH) (2mg/l) resistance test.
Mycobacteriums other than M. tuberculosis complex
were excluded from the analysis [10].
Drug susceptibility tests were performed using the
simplified variant of the indirect proportion method on
L-J medium. The proportion method (Canetti modified)
determines the percentage of growth (number of col-
onies) of defined inoculums on a drug-free controlmedium versus growth on culture media containing the
critical concentration of an anti- tuberculosis drug. The
critical drug concentration, as well as the critical propor-
tion of resistant colonies were been evaluated from clin-
ical data. Resistance was expressed as the percentage of
colonies that grew on recommended critical concentra-
tions of the drugs tested (i.e. 0.2 mg/l for isoniazid
(INH), 2 mg/l for ethambutol (EMB), and 4 mg/l for
streptomycin (STM) and 40 mg/l for rifampicin (RIF).
The criterion used for drug resistance was growth of 1%
or more of the bacterial population on media containing
the critical concentration of each drug. The results of
the tests were recorded on standardized forms [10].
Data collection procedures
Laboratory based retrospective study was done among
TB patients who had retreated for first line anti-
tuberculosis drugs. Participant demographic variable,
drug susceptibility test results of Mycobacterium tuber-
culosis (MTB) were carefully collected from the labora-
tory registration book using a standardized check list.
The overall activities of data collection were monitored
by the principal investigator and there was strict super-
vision during data collection. Only those patients with
full information recorded in the registration book were
included in the study. The extracted variables were age,
sex, year of treatment, smear sample, drug resistance.
Risk factors for drug resistance could not be evaluated
as there was insufficient data in the charts.
Operational definitions
Resistance in new cases (primary) was defined as in vitro
resistance in patients who did not have a history of anti-
TB treatment, while retreatment resistance (secondary)
was defined as in vitro resistance in patients previously
treated with any anti-TB medication. The definition of
MDR-TB cases recommended by WHO and IUATLD is
the pattern of drug resistance to at least INH and RIF.
Resistance to more than one agents except these agents
was referred to as poly drug resistance TB (PDR-TB)
[11].
Data management and analysis
Data collected in this study were used to ascertain the
percentage of drug resistance in each year, to any drug,
each drug either alone or in combination with other
drugs. The percentage of resistant isolates from patients
was calculated by dividing the number of resistant iso-
lates in each of the categories by the total number of iso-
lates tested for that drug or combination of drugs. We
evaluated temporal trends in resistance to each drug
alone or in combination with other drugs, as well as
trends in multidrug resistance. The chi square test for
trend was used to assess percentage resistance by year of
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ducted using SPSS Version 16.0 software (SPSS INC,
Chicago, IL, USA).
Ethical consideration
Ethical clearance for the conduct of this study was
obtained from St. Peter’s TB Specialized Hospital Ethical
Review Committee and Institutional Ethical Review
Committee of Addis Ababa University, Faculty of Medi-
cine; School of Medical Laboratory Science. Names or
identification number of study participants were not
included from the data collection template.
Findings
A total of 376 distinct cultures positive retreated cases
(previously treated with first line anti- TB drugs for at
least one month) cases were identified from January
2004 to December 2008 at St. Peter’s TB Specialized
Hospital Laboratory registration book. Of these 235
(62.5%) were male and the age range of the study popu-
lation was 9 -74years (Mean age, 31.9), median age of 28
(9–76). Of these 87.5% was in age range of 15 – 49. The
study population was 69, 83, 86, 74 and 64 across per
year, respectively (Table 1).
Among 376 culture positive for M. tuberculosis one
hundred and two (27.1%) were susceptible to all of the
four first line anti-TB drugs -Isoniazid, Rifampicin, Eth-
ambutol & Streptomycin, and 274 (72.9%) were resist-
ance to at least one drug. Resistance to any STM (67.3%)
was found to be the most common followed by (56.1%)
INH, (46.1%) RIF and (43.5%) ETB (Figure 1).Table 1 Socio-demographic characteristics of the study
participants, St. Peter’s TB Specialized Hospital, 2011






<15 Years 7 1.8
15-49 Years 329 86.8








Total 376 100Seventy one (18.9%) were resistant to only a single
drug while more than one drug resistance includes both
poly resistance and MDR-TB. so that it should be 203
(203/376=54%) were resistant to two or more drugs.
Among mono resistance, Streptomycin 56 (78.8%) was
found to be highest proportion, followed by isoniazid.
However, our result showed no mono resistant strain for
Rifampicin.
Poly resistance was reported in 29 (7.7%) of the cases.
Among these, the highest proportion was 15(53.6%) Iso-
niazid + Streptomycin Combination. In this study the
prevalence of MDR-TB (defined as the resistance to at
least INH and RIF) 174 (46.3%) was found to be high
(Table 2). Among these, 103 (59.2%) were males and 154
(90.8%) were between age range of 15 – 49 years. Out of
MDR-TB cases 140 (80.5%) cases were resistant for all
first line anti-TB drugs.
Any drug resistance as well as MDR-TB was not statis-
tically significantly associated with any age group. How-
ever, there was statistically significant association
between any drug resistances among gender, specifically
male patients (P < 0.05) (Table 3). Trends in resistance
rate among re-treatment cases from 2004 to 2008
showed a statistically significant increase for any drug as
well as for INH, RIF, and MDR resistance (P <0.05 for
trend) (Figure 2).
Discussion
In the present study, 102 (27.1%) of the cases were sus-
ceptible to all of the four first line anti-TB drugs and
274 (72.9%) were resistant to at least one or more anti-
TB drugs indicating higher prevalence of drug resistant
TB for first line anti-TB drugs than studies conducted in
Ethiopia with overall resistance to any anti-TB drugs
ranges from 14% -27% [12-16]. The higher magnitude of
resistance to any anti-TB drugs in the present study
could be explained the difference in the characteristics
study subjects (retreatment cases) which is more likely
to have resistance and majority of retreatment cases in
the country referred to the study hospital.
Mono resistance to streptomycin (14.9%) was found to
be the highest proportion among first line anti-TB drugs
which is consistent with WHO global surveillance report
[5] as well as in other studies conducted in Denmark,
Turkey, India and Arsi zone of Ethiopia [17-20]. In con-
trast a 15-year surveillance in Saudi Arabia showed, re-
sistance to INH and EMB was more frequent than to
other first-line drugs [21].
MDR-TB in retreatment patients varies from 30% to
80% in different regions [22] and in Ethiopia, MDR –TB
prevalence in 2008 was (0.9%–2.8%) for new cases and
(5.6%–21%) for retreatment cases [2].
In this study, MDR-TB was found in 46.3% of retreat-
ment; this shows a higher percentage of MDR-TB in
 H = Isoniazid 
R = Rifampicin  
E = Ethambutol 
S = Streptomycin  
Figure 1 Frequency of First line Tuberculosis Drug resistance in St. Peter's TB Specialized Hospital, 2011.
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WHO report [2]. Surprisingly, our study noted that
MDR-TB prevalence is significantly higher in male than
female patients which are inconsistent with a report by
O’Donnell MR et al. where female have more risk thanTable 2 Pattern of drug resistance among 376 cultures
positive retreatment cases, St. Peter’s TB specialized
Hospital, 2011
Pattern of drug resistance Frequency Percentage (%)





Single drug 71 18.9
Mono INH Resistant 11 2.9
Mono RIF Resistant 0 0
Mono ETB Resistant 4 1.1
Mono STM Resistant 56 14.9
Two drug
INH+ RIF 4 1.1
INH+ ETB 2 0.53
INH+ STM 15 4.0
RIF + ETB 0 0
RIF + STM 0 0
ETB+ STM 0 0
Three or more drug
INH+ RIF + ETB 2 0.53
INH+ RIF + STM 28 7.5
INH+ ETB + STM 12 3.2
RIF + ETB + STM 0 0
INH+ RIF + ETB + STM 140 37.2
MDR5 174 46
1INH= Isoniazid, 2RIF = Rifampicin, 3ETB,= Ethabutol, 4STM, = Streptomycin,
5MDR=Multi drug resistance (resistance at least INH and RIF).male patients [23]. The latter study explained as gender
differences in drug-resistant TB in areas of HIV endem-
icity and low prevalence suggest a possible effect of the
HIV/AIDS epidemic on prevalence of drug-resistant TB
in women [24]. Despite such difference, male or female
TB patients could have different levels of risks for drug
resistance due to differences in access to health-care ser-
vices or exposure to other risk factors. Discovering gen-
der disparities associated with the risks of MDR-TB
could provide insight into the development of targeted
measures and improve access to health care and reduce
the risk of acquiring drug-resistance.
The association between age and the risk of MDR-TB
is not well established in the literatures as different stud-
ies use different cut-off points for age groups. MDR-TB
patients were more likely to be younger than 65 years
[24,25]. A systematic review analysis in Europe revealed
the pooled risk of MDR-TB for people younger than 45
was higher than that among older patients (OR: 1.52,
95% CI: 1.13-2.03) [24]. In this study, we did not found a
statistical significant association between patient’s age
and frequency of MDR-TB which was in contrast with a
report by Shao et al. indicating MDR –TB was much
higher in young adulthoods and peaked at 35–44 years
old [26].
The trend in drug resistance against all first-line drugs
shows a significant increase. This remarkable percentage
of drug resistance among retreatment patients supports
the idea of inefficiency in TB control programs and ir-
regular/improper anti-TB drug use in recent years,
which have led to accumulation and multiplication of re-
sistant strains. Notably, resistance to the other corner
stone of anti-TB therapy, RIF mono resistance, was not
observed in current study, but there is a significant in-
crease in proportion of INH resistance which may be
considered as an alarming sign and indicates further
transmission of resistant strains in the community.
The study has its own limitations. There is a potential
bias in estimation of drug resistance in previously trea-
ted cases and the data were taken from the hospital, it
Table 3 Characteristics of culture positive retreatment cases according drug resistance pattern, St. Peter’s TB
Specialized Hospital, 2011
Variable N (%) Any drug resistance n (%) P-value MDR-TB n, (%) P-value
Sex
Male 235 (62.5) 154 (59) 0.03 103 (59.2) 0.220
Female 141 (37.5) 107 (41) 71 (40.8)
Age(yr)
<15 7 (1.9) 5 (1.9) 0.990 4 (2.3)
15–49 330 (87.8) 235 (90) 0.395 158 (90.8) 0.689
>49 39 (10.4) 21 (8) 12 (6.9) 0.333
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sible to get other relevant variables such as co-morbidity,
HIV status. In resource poor settings where the quality
of reports are often questionable and the retrospective
data collected primarily for reporting may not be robust
[27].
Conclusions
In conclusion, the high prevalence of drug resistance in
this study area may limit the success of TB control pro-
gram. Increased trend in resistance to anti-TB drug
among re-treatment cases were noted. So this signifies
that establishing advanced diagnostic facilities for early de-
tection of MDR-TB. Monitoring of drug-resistance should
be enhanced by periodic surveys to assess trends and take
correct actions when necessary. Prevention and control of
drug-resistant TB should be emphasized by the revised
DOTS program through prompt case detection, routine
and quality-assured DST for those patients at high risk of
resistance, proper administration of anti-TB drugs accord-
ing to the recommended national guidelines and strength-
ening national DOTS program, expanding second line
treatment used for treating the existing cases and help to
protect its transmission, This enables to appropriatelyFigure 2 Trend in drug resistance to anti-TB drugs in re-
treatment cases, St. Peter’s TB Specialized Hospital, 2011.manage TB patients and to lower the rate of MDR-TB
among retreatment cases. In addition further studies and
continued surveillance of the resistance pattern of M. tu-
berculosis is needed to further delineate the risk factors
and to formulate the plans for the future management of
tuberculosis in high MDR-TB settings.
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